Neuroscience and Behavioral Physiology

, Volume 44, Issue 2, pp 187–194

Comparative Assessment of the Efficacy of Valdoxane (agomelatine) in Recurrent Depression and Bipolar Affective Disorder


DOI: 10.1007/s11055-014-9895-4

Cite this article as:
Tyuvina, N.A. & Smirnova, V.N. Neurosci Behav Physi (2014) 44: 187. doi:10.1007/s11055-014-9895-4

A comparative analysis of the efficacy and safety of the treatment of depression with Valdoxane in the framework of recurrent depressive disorder (RDD, 22 cases) and bipolar affective disorder (BAD, 23 cases) is presented. Valdoxane was given at night at a dose of 25–50 mg/day for eight weeks. Treatment efficacy was assessed using the HAM-D-17, CGI-S, and CGI-I psychometric scales, along with visual analog scales for assessment of going to sleep, nocturnal sleep quality, morning status, and daytime activity. The agent produced antidepressant effects by treatment week 1, along with normalization of circadian rhythms. By the end of treatment, the proportion of responders in the BAD group was 90.9%, compared with 91.3% in the RDD group; the proportions of patients in remission were 65.2% and 54.5%. These results lead to the conclusion that Valdoxane is effective in both bipolar and recurrent depression regardless of the severity of the conditions. Valdoxane produced no adverse side effects and no risk of phase inversion and/or transient hypomania in BAD.


Valdoxanebipolar affective disorderrecurrent depressiontreatment

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Psychiatry and Medical PsychologyI. M. Sechenov First Moscow State UniversityMoscowRussia